Table 1.
Treatment group |
||
CAPIRI | CAPIRI-Bev | |
N (%) | 17 (37%) | 29 (63%) |
Age (median), years (range) | 66 (55-81) | 60 (37-80) |
Gender, M/F | 9/8 | 22/7 |
Site of primary tumor, n (%) | ||
Rectum | 7 (41.2) | 15 (51.7) |
Colon | 10 (58.8) | 14 (48.2) |
Site of metastases, n (%)1 | ||
Hepatic | 12 (71) | 24 (83) |
Pulmonary | 6 (35) | 11 (38) |
Lymphatic and nodal | 4 (24) | 17 (59) |
Skeletal | 1 (6) | 4 (14) |
Peritoneal | 1 (6) | 5 (17) |
Other sites | 6 (35) | 5 (17) |
Performance status (Karnofsky) | ||
100% | 4 (23.5) | 17 (58.6) |
90% | 1 (5.9) | 5 (17.2) |
85% | 1 (5.9) | 0 (0) |
80% | 2 (11.8) | 3 (10.3) |
70% | 4 (23.5) | 0 (0) |
Adjuvant chemotherapy received | 8 (47%) | 8 (27.6%) |
Patients could have more than one metastatic site.